Trial Profile
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Thromboembolism
- Focus Pharmacokinetics
- 22 Dec 2020 Results published in the Nephrology Dialysis Transplantation
- 15 Oct 2018 Status changed from recruiting to completed.
- 26 Jul 2016 New trial record